This CPB is revised to state that plasmapheresis is considered medically necessary for the following indications: hemolytic uremic syndrome; catastrophic antiphospholipid syndrome; anti-neutrophil cytoplasmic antibody-associated vasculitis unresponsive to conventional therapy; and paraproteinemic demyelinating neuropathies associated with IgA, IgG or IgM monoclonal gammopathy of undetermined significance (MGUS). This CPB has been revised to state that plasmapheresis is considered experimental and investigational for hypertriglyceridemia, macular degeneration, and septic shock.